Cerenome Announces Up to $20 Million Financing Facility with Royalty-Based Repayment

Cerenome secures up to $20 million in royalty-based financing, extending its forecast cash runway well into 2028.

Rhea-AI Summary

Cerenome (CNSY) entered a senior secured financing agreement with 3i Fund for a facility of up to $20 million with royalty-based repayments.

The company received an initial tranche at closing, with additional tranches contingent on achieving specified milestones. Proceeds are intended to support commercial scale-up and development of the CNSide cerebrospinal fluid assay platform and other proprietary laboratory-developed tests. Cerenome describes the structure as designed to be minimally dilutive to stockholders while funding CNSide sales growth and pipeline expansion. The company now forecasts its cash runway to extend well into 2028, based on this facility, other existing facilities, current cash, and expected CNSide-related sales and cash flow.

Positive

• Financing facility up to $20 million via senior secured, royalty-based structure
• Initial funding received at closing with further tranches available upon milestones
• Forecast cash runway now extends well into 2028

Negative

• Royalty-based repayments commit a portion of future revenue or cash flows
• Future tranches depend on achieving specified milestones and are not guaranteed

News Explained

Funding has started, but the initial amount is undisclosed; June 30 liquidity equaled 109.6 days of last reported operating cash use.

Cerenome says it received an initial tranche at closing, but the release does not state its amount, so the immediate liquidity added by the facility cannot be quantified.

As of June 30, 2026, the company reported $2.366 million of cash and $6.221 million of short-term investments; those holdings equal 109.6 days of its last reported operating cash use.

The company identifies a forthcoming Form 8-K for additional transaction details, leaving that filing as the named resolution point for the tranche amount and repayment mechanics.

Sources and calculations

• Cerenome financing facility announcement (2026-09-10)
• Cerenome second-quarter 2026 fundamentals (2026Q2)

• Available liquidity against the last reported quarterly operating outflow, in days at that rate ($2,366,000 + $6,221,000) / ($7,132,000 / 91) = 109.6 days

Argus 15 min delay

+6.83% vs previous close $2.66 last price 0.1x rel. volume Open Argus

Details

Market reaction after royalty financing facility: CNSY +6.83%

$2.50 $2.75 Day Range

$20.19M Market Cap

Following this news, CNSY has gained 6.83%, reflecting a notable positive market reaction. The stock is currently trading at $2.66.

Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.

Market Context

On Aug 14, Cerenome reported $8.6 million in cash, cash equivalents and investments alongside a $9.1...

Analysis

On Aug 14, Cerenome reported $8.6 million in cash, cash equivalents and investments alongside a $9.1 million operating loss; the new facility adds financing capacity for the stated CNSide scale-up.

Key Figures

Financing facility: Up to $20 million Cash runway: Into 2028

Financing facility

Up to $20 million

Senior secured facility with royalty-based repayments

Cash runway

Into 2028

Forecast including the facility, existing facilities, cash and CNSide-related sales and cash flow

Historical Context

2 past events · Latest: Aug 14

2 events

1. Aug 14

   Q2 financial results

   24h Move

   -12.9%

   Reported $8.6 million in cash alongside a $9.1 million operating loss.

2. Aug 13

   Coverage expansion

   24h Move

   -0.8%

   Expanded CNSide contracted access beyond its full-year 2026 coverage objective.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

senior secured facility, royalty-based repayments, laboratory-developed tests, csf

4 terms

senior secured facility financial

"entered into a financing agreement with 3i Fund for a senior secured facility"

A senior secured facility is a loan or credit line that a company borrows where lenders have first claim on specific assets if the borrower can’t repay. Think of it as a mortgage-like pledge combined with being first in line to get paid back, which lowers the lender’s risk. Investors care because it affects a borrower’s default risk and recovery prospects—senior secured debt is generally safer than unsecured or junior debt and influences a company’s borrowing cost and capital structure.

royalty-based repayments financial

"senior secured facility of up to $20 million with royalty-based repayments"

A royalty-based repayment is a financing arrangement where a lender or investor is paid a fixed percentage of a company’s revenues or product sales over time, rather than receiving regular fixed-interest payments or owning equity. These payments continue until a predetermined cap is reached or for a set period, so cash outflows rise and fall with the business’s sales; for investors this changes risk and return profiles by linking repayment directly to performance, like renting a slice of future revenue.

laboratory-developed tests technical

"scale-up of the Company’s proprietary laboratory-developed tests"

Laboratory-developed tests are medical tests that a single clinical laboratory designs, builds and runs internally rather than buying from outside manufacturers. Think of them as an in-house recipe a lab creates to detect a disease or measure a biomarker; they matter to investors because they can drive revenue, offer faster product development and carry distinct regulatory and reimbursement risks that affect a healthcare company's financial outlook.

csf medical

"CNSide cerebrospinal fluid (CSF) assay platform"

Cerebrospinal fluid (CSF) is the clear liquid that surrounds and cushions the brain and spinal cord, carrying nutrients and waste away from nervous tissue much like coolant and filters protect an engine. In clinical and regulatory news, CSF measurements are used to detect disease markers, track a drug’s effect on the central nervous system, or signal safety issues; changes in CSF test results can materially affect the perceived efficacy, market potential, and regulatory outlook for neuroscience-focused companies.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Capital will support continued CNSide^® commercial scale-up and development

Initial tranche of funding provided at closing with future tranches linked to milestones

Forecasted cash runway now into 2028

HOUSTON, Sept. 10, 2026 (GLOBE NEWSWIRE) -- Cerenome, Inc. (Nasdaq: CNSY) ("Cerenome" or the "Company"), a CNS oncology company advancing an integrated platform of precision diagnostics, targeted therapeutics, and artificial intelligence, today announced that it has entered into a financing agreement with 3i, LP (“3i Fund”) for a senior secured facility of up to $20 million with royalty-based repayments. Under the agreement, the Company received initial funding at closing, with future tranches available upon achieving certain milestones.

The financing is intended to support the scale-up of the Company’s proprietary laboratory-developed tests, particularly its CNSide^® cerebrospinal fluid (“CSF”) assay platform.

“Cerenome is grateful for the support of the 3i Fund team, and we look forward to a long-term relationship,” said Andrew Sims, Cerenome’s Chief Financial Officer. “This facility is designed to be minimally dilutive to stockholders while supporting the next stage of commercial scale-up and development of CNSide, specifically growing sales and broadening the pipeline. We forecast our cash runway is now well into 2028 when we consider, the 3i facility, other existing facilities along with current cash and forecasted CNSide related sales and cash flow.”

Additional transaction details are included in a Current Report on Form 8-K to be filed by the Company with the U.S. Securities and Exchange Commission.

About Cerenome

Cerenome (Nasdaq: CNSY) is a CNS oncology company advancing an integrated platform that combines precision diagnostics, targeted therapeutics, and artificial intelligence to improve outcomes for patients with central nervous system cancers. The Company’s CNSide^® Diagnostics platform supports the detection, molecular characterization, and longitudinal monitoring of CNS cancers through cerebrospinal fluid-based testing. Its lead therapeutic platform, REYOBIQ™ (rhenium Re186 obisbemeda), is being evaluated in clinical trials for leptomeningeal metastases, recurrent glioblastoma, and pediatric brain cancers. The data & artificial intelligence platform is designed to integrate diagnostic, molecular, imaging, and clinical data into actionable insights that support precision oncology and therapeutic innovation. By integrating commercial diagnostics, targeted therapeutics, proprietary longitudinal data, and artificial intelligence within a single organization, Cerenome is building a differentiated CNS oncology platform designed to improve patient care while creating long-term shareholder value. Visit https://www.cerenome.com.

About CNSide Diagnostics, LLC

CNSide Diagnostics, LLC is a wholly owned subsidiary of Cerenome, Inc. that develops and commercializes proprietary laboratory-developed tests, such as CNSide^®, designed to identify tumor cells that have metastasized to the central nervous system in patients with carcinomas and melanomas. The CNSide^® CSF Assay Platform enables quantitative analysis of the cerebrospinal fluid that informs and improves the management of patients with leptomeningeal metastases. For more information, visit https://www.cnside-dx.com/.

Forward-Looking Statements

This press release contains statements that may be deemed “forward-looking statements” within the meaning of U.S. securities laws, including statements regarding the financing agreement with 3i Fund, the timing and availability of additional funding tranches, the achievement of milestones under the agreement, the use of proceeds from the financing, clinical trials, expected operations, and upcoming developments. All statements in this press release other than statements of historical fact are forward-looking statements. These forward-looking statements may be identified by future verbs, as well as terms such as “expect,” “potential,” “anticipating,” “planning” and similar expressions or the negatives thereof. Such statements are based upon certain assumptions and assessments made by management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. These statements include, without limitation, statements regarding the timing and amount of additional tranches under the financing agreement, the Company’s ability to achieve the milestones required to receive such tranches, the anticipated use of proceeds from the financing, the Company’s future royalty obligations to 3i Fund, the Company’s anticipated growth in CNSide testing volume and reimbursement, the timing and results of REYOBIQ clinical trials, and expectations as to the Company’s future performance and financial position. Actual results may differ materially from those expressed or implied by these forward-looking statements due to a variety of risks and uncertainties, including those described in the Company’s filings with the Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.

Investor Contact
CORE IR
IR@cerenome.com

FAQ

How will Cerenome use the proceeds from the 3i Fund financing facility?

Proceeds are intended to support the scale-up of Cerenome’s proprietary laboratory-developed tests, with a particular focus on its CNSide cerebrospinal fluid assay platform. The company also aims to use the facility to support the next stage of CNSide commercial scale-up and development, including growing sales and broadening the pipeline.

What is the structure of Cerenome’s new financing agreement with 3i Fund?

The agreement is a senior secured facility of up to $20 million with royalty-based repayments. Cerenome received an initial tranche of funding at closing, and additional tranches will be available upon the achievement of certain milestones.

Why does Cerenome describe this financing as minimally dilutive to stockholders?

Cerenome’s Chief Financial Officer stated that the facility is designed to be minimally dilutive to stockholders while funding the next stage of CNSide commercial scale-up and development. This reflects the company’s characterization of the financing structure compared with more equity-heavy alternatives.

Where can investors find more details about the Cerenome and 3i Fund transaction?

Additional transaction details will be included in a Current Report on Form 8-K to be filed by Cerenome with the U.S. Securities and Exchange Commission.